Scientists repurposed a blood cancer treatment using genetically modified immune cells called CAR T cells to reverse age-associated tissue damage.(selvanegra | iStock)
Genetically modified immune cells taken from patients and then reintroduced called chimeric antigen receptor (CAR) T cells have gained notoriety for treating blood cancers. But could these re-engineered immune cells be used to treat other conditions like aging?
Lowe and colleagues from the Sloan Kettering Institute in New York published a study in Nature where they deployed CAR T cells against other diseased tissues. These diseased tissues were adversely impacted by senescence—an age-associated state of arrested cell proliferation and elevated inflammation. Doctors may one day use this potential therapy to treat a wide array of senescence-associated ailments, such as fibrotic liver disease, atherosclerosis, and diabetes.
When used in cancer treatment, doctors remove immune cells called T cells from a patient and engineer them so that they can target cancer cells before returning them to the body. When they are reintroduced into the patient, the CAR T cells locate and destroy cancer cells with precision and accuracy.
But for CAR T cell therapy to be successful, the cells must have a good target. Accordingly, the first FDA-approved CAR T cells target a cell-surface molecule on blood cancer cells called CD19 that presents on cancer cells but few normal cells. Taking this prior work into account, Lowe and colleagues sought to identify a molecular target on senescent cells.
“Senescence is a double-edge sword,” said Scott Lowe, Ph.D., a senior author on the paper in a press release. “Cells in this state play an important role in wound healing and cancer deterrence. But if they linger for too long, they can cause chronic inflammation, which itself is a cause of many diseases. Finding a way to safely eliminate these cells would be a major therapeutic breakthrough in the treatment of these diseases.”
As for the role of senescent cells in disease, the authors wrote, “the aberrant accumulation of senescent cells generates an inflammatory milieu that leads to chronic tissue damage and contributes to diseases such as liver and lung fibrosis, atherosclerosis, diabetes, and osteoarthritis.” They added that eliminating senescent cells from damaged mouse tissue “ameliorates the symptoms of these pathologies and even promotes longevity.”
The researchers compared molecules on the surface of senescent cells to other cell types to identify a molecular characteristic that distinguishes senescent cells from other cell types. In doing so, they identified a molecule called urokinase plasminogen activator receptor (uPAR) enriched on these cells. uPAR molecules are mostly absent on other cell types. The scientists examined cells in which they induced senescence to identify this cell surface marker. They compared protein levels between senescent cells and other cell types by measuring the presence of molecules indicative of protein expression called ribonucleic acid (RNA). In this way, they specifically identified uPAR on the cell surface of senescent cells.
The team then designed CAR T cells that recognize uPAR so that the re-engineered immune cells could target senescent cells presenting uPAR. To test whether the re-engineered CAR T cells actually destroy senescent cells, they examined whether these CAR T cells would engulf and dispose of liver cells with genetically-induced senescence (oncogene-induced senescence). They found effective clearance of senescent liver cells within 10 days of treatment. They concluded that their designed CAR T cells can eliminate senescent cells in laboratory dishes.
To see if this treatment scheme was effective in live animals, the research team treated live mice with different diseases that cause senescence using these CAR T cells. In a disease mouse model of lung cancer, they found that the CAR T cell treatment prolonged the survival and reduced the presence of lung tumor cells.
They also examined the effectiveness of the CAR T therapy on a couple of models of liver fibrosis, which causes cell senescence. They found that CAR T cell treatment also reduced the presence of senescent cells in mice given a molecule that induced liver fibrosis called carbon tetrachloride. CAR T cell treatment targeting uPAR also significantly reduced senescent cell concentrations in another form of diet-induced liver fibrosis called non-alcoholic steatohepatitis.
These results indicated that CAR T cell treatment works to clear senescent cells not only in cells of laboratory dishes but also in live mice. “This study demonstrates that T cell engineering and CAR therapy can be effective beyond cancer immunotherapy,” said Michael Sadelain, MD, Ph.D., an author of the study in the press release.
The next steps will be to find out whether uPAR targeting CAR T cells can combat other senescence-related diseases like atherosclerosis, diabetes, and osteoarthritis. This research team hopes to eventually develop this CAR T therapy for use in people.
“We think this approach has the potential to tackle a number of senescence-related diseases for which new treatments are badly needed,” added senior author Scott Lowe, Ph.D.